Portal de Periódicos da CAPES

3-[(1 S ,2 S ,3 R )-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma

2019; American Chemical Society; Volume: 62; Issue: 15 Linguagem: Inglês

10.1021/acs.jmedchem.9b00719

1520-4804

Rui Xu, Keshi Wang, James P. Rizzi, Heli Huang, Jonas Grina, Stephen T. Schlachter, Bin Wang, Paul M. Wehn, Hanbiao Yang, Darryl D. Dixon, Robert Czerwiński, Xinlin Du, Emily L. Ged, Guangzhou Han, Huiling Tan, Tai‐Tong Wong, Shanhai Xie, John A. Josey, Eli M. Wallace,

Hepatocellular Carcinoma Treatment and Prognosis

The hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in clear cell renal cell carcinoma (ccRCC). Our first HIF-2α inhibitor PT2385 demonstrated promising proof of concept clinical activity in heavily pretreated advanced ccRCC patients. However, PT2385 was restricted by variable and dose-limited pharmacokinetics resulting from extensive metabolism of PT2385 to its glucuronide metabolite. Herein we describe the discovery of second-generation HIF-2α inhibitor PT2977 with increased potency and improved pharmacokinetic profile achieved by reduction of phase 2 metabolism. Structural modification by changing the geminal difluoro group in PT2385 to a vicinal difluoro group resulted in enhanced potency, decreased lipophilicity, and significantly improved pharmacokinetic properties. In a phase 1 dose-escalation study, the clinical pharmacokinetics for PT2977 supports the hypothesis that attenuating the rate of glucuronidation would improve exposure and reduce variability in patients. Early evidence of clinical activity shows promise for PT2977 in the treatment of ccRCC.